JPRN-jRCT2031230267进行中（未招募）3 期
A Phase III b, single-arm, multicenter, optimal dose finding study to assess the efficacy and safety of P1101 in Japanese patients with polycythemia vera (PV).
Kawase Hiroaki0 个研究点目标入组 20 人开始时间: 2023年7月29日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1. Male or female patients >=18 years old at the time of informed consent to participate in the study
- •2. Patients diagnosed with PV according to the WHO 2008 or 2016 criteria
- •3. Patients with PV who have the inadequate response to an existing therapy or whom the existing therapy is inappropriate to apply
- •4. Patients who have given written informed consent to participate in this study
排除标准
- •1. Any contraindications to interferon alfa or hypersensitivity to interferon alfa
- •2. Subjects who stopped prior to interferon alfa therapy due to low efficacy or poor tolerability
- •3. Subjects with severe or serious diseases that the Investigator determines may affect the subject's participation in this study
- •4. History of major organ transplantation
- •5. Pregnant or breastfeeding women
研究者
相似试验
已完成
3 期
A phase III clinical trial to assess efficacy and safety of YW17 (laronidase; CinnaGen)Patients with Mucopolysaccharidosis type I (MPS I).Mucopolysaccharidosis, type IE76.0IRCT20150303021315N30CinnaGen company12
进行中（未招募）
1 期
An international study of durvalumab in combination with platinum and etoposide for the treatment of small cell lung cancerExtensive-stage Small Cell Lung CancerEUCTR2020-005537-32-BGAstraZeneca AB150
进行中（未招募）
1 期
An international study of durvalumab in combination with platinum and etoposide for the treatment of small cell lung cancerMedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Extensive-stage Small Cell Lung CancerEUCTR2020-005537-32-CZAstraZeneca AB150
进行中（未招募）
1 期
An international study of durvalumab in combination with platinum and etoposide for the treatment of small cell lung cancerExtensive-stage Small Cell Lung CancerEUCTR2020-005537-32-DEAstraZeneca AB150
进行中（未招募）
1 期
An international study of durvalumab in combination with platinum and etoposide for the treatment of small cell lung cancerMedDRA version: 21.1Level: PTClassification code 10041068Term: Small cell lung cancer extensive stageSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Extensive-stage Small Cell Lung CancerEUCTR2020-005537-32-ITASTRAZENECA AB150